Livtencity (maribavir) by Takeda – FDA Approved Drug for Cytomegalovirus treatment
Livtencity is the first drug to be approved by US FDA for the treatment of Cytomegalovirus. This approval is specifically for the use in patients with post-transplant cytomegalovirus (CMV) infection or disease, failing to respond to the available antiviral treatments. Livtencity’s FDA approval is awarded with Breakthrough Therapy and Priority Review Designations. Livtencity works by…
News Views